Solid Biosciences (SLDB) Accumulated Depreciation (2017 - 2025)

Solid Biosciences (SLDB) has 9 years of Accumulated Depreciation data on file, last reported at $14.2 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation rose 8.94% year-over-year to $14.2 million; the trailing twelve-month figure through Dec 2025 stood at $14.2 million (up 8.94% YoY), and the FY2025 full-year result was $14.2 million, up 8.94% from the prior year.
• Accumulated Depreciation rose to $14.2 million in Q4 2025, from $13.0 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $14.2 million in Q4 2025 to a low of $9.4 million in Q3 2022.
• A 5-year average of $11.7 million and a median of $11.7 million in 2021 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation surged 62.23% in 2021 and retreated 13.61% in 2022, its largest moves.
• Tracing SLDB's Accumulated Depreciation over 5 years: stood at $11.7 million in 2021, then slipped by 6.05% to $11.0 million in 2022, then increased by 16.24% to $12.7 million in 2023, then climbed by 2.29% to $13.0 million in 2024, then rose by 8.94% to $14.2 million in 2025.
• Business Quant data shows SLDB's Accumulated Depreciation at $14.2 million in Q4 2025, $13.0 million in Q4 2024, and $13.1 million in Q1 2024.